What does this research mean for the field?

Soluble c-Met levels are elevated in the cerebrospinal fluid and plasma of newly diagnosed, treatment-naïve multiple sclerosis patients compared to controls, and correlate with neurofilament light chain and glial fibrillary acidic protein levels, indicating a link to CNS injury. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To investigate the correlation of soluble c-Met with neuroinflammatory biomarkers in multiple sclerosis and controls.

February 25, 2026Open Access

Soluble c-met correlates with NFL and GFAP levels in the CSF of patients with multiple sclerosis

Puntos clave

To investigate the correlation of soluble c-Met with neuroinflammatory biomarkers in multiple sclerosis and controls.
Measured levels of soluble c-Met, HGF, ADAM10/ADAM17, NfL, and GFAP in CSF and plasma.
Compared newly diagnosed, treatment-naïve MS patients with non-inflammatory neurological disease controls.
Examined correlations between soluble c-Met and neuroinflammatory markers in both CSF and plasma.
Soluble c-Met levels were significantly higher in CSF and plasma of MS patients compared to controls.
Positive correlations found between CSF soluble c-Met and both NfL (ρ = 0.531, p = 0.011) and GFAP (ρ = 0.525, p = 0.007).
Plasma ADAM10 levels were significantly decreased in MS patients, indicating altered regulation of c-Met shedding.

Resumen

The hepatocyte growth factor (HGF)/c-Met pathway plays an important role in several inflammatory conditions, regulating phenotypic plasticity within both myeloid and lymphoid cell populations. c-Met was recently identified as a marker of a distinct subset of highly pro-inflammatory and pro-migratory CD4 + T cells that are enriched in both the blood and cerebrospinal fluid of patients with multiple sclerosis. Soluble c-Met is a cleaved form of the c-Met receptor, released by the disintegrin metalloproteinases ADAM10 and ADAM17. Its role in inflammation is not well understood, and concentrations vary in the blood across different conditions. In this prospective comparative study, soluble c-Met, HGF, soluble ADAM10/ADAM17, and biomarkers of CNS injury—neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP)—were measured in newly diagnosed, treatment-naïve MS patients ( n = 29) and non-inflammatory neurological diseases (NIND) controls ( n = 21). Correlations between soluble c-Met and these markers were examined in CSF and plasma. Soluble c-Met concentrations were significantly higher in both CSF and plasma of MS patients compared with controls, whereas HGF levels did not differ. Among the two proteases, ADAM10 was significantly decreased in plasma of MS patients. In CSF, soluble c-Met correlated positively with NfL (ρ = 0.531, p = 0.011) and GFAP (ρ = 0.525, p = 0.007), while no significant correlations were observed in plasma. Elevated intrathecal soluble c-Met in MS is associated with markers of neuroaxonal and astroglial injury, suggesting compartment-specific c-Met shedding that may reflect ongoing CNS pathology. • First study to examine soluble c-Met in paired plasma and CSF from newly diagnosed MS patients. • Soluble c-Met is elevated in both CSF and plasma of MS patients compare to the control. • CSF c-Met correlates with NfL and GFAP, linking it to neuroaxonal and glial injury. • Plasma ADAM10 is reduced in MS, suggesting altered regulation of c-Met shedding. • Findings support compartment-specific c-Met shedding in early MS pathology.

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo